Filter Results:
(1,245)
Show Results For
- All HBS Web
(1,245)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
Show Results For
- All HBS Web
(1,245)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross." Harvard Business School Supplement 293-070, October 1992. (Revised April 1993.)
- June 1990
- Teaching Note
International Pharmaceuticals Inc. (Abridged), Teaching Note
By: James E. Austin and Tomas Otto Kohn
Keywords: Pharmaceutical Industry
- 1995
- Chapter
Pharmaceutical Companies and Health Care Reform
By: Arthur A. Daemmrich
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (E): Judge Stein Rules
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (E): Judge Stein Rules." Harvard Business School Supplement 806-081, January 2006. (Revised May 2007.)
- March 1993 (Revised September 1995)
- Teaching Note
Note on Pharmaceutical Industry Regulation TN
Teaching Note for (9-792-002). View Details
- 2018
- Chapter
Pharmaceutical Trends, Not What They Seem
By: Kyle Myers and Mark Pauly
Myers, Kyle, and Mark Pauly. "Pharmaceutical Trends, Not What They Seem." In Managing Discovery in the Life Sciences: Harnessing Creativity to Drive Biomedical Innovation, by Philip A. Rea, Mark V. Pauly, and Lawton R. Burns, 18–42. Cambridge: Cambridge University Press, 2018.
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
Keywords: LEAD; Talent Management; Leadership And Change Management; Change Management; Organizational Change and Adaptation; Restructuring; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)." Harvard Business School Case 415-013, March 2015.
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (C): April 1991
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (C): April 1991." Harvard Business School Supplement 293-071, October 1992. (Revised March 1993.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B2): Henry McCance
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B2): Henry McCance." Harvard Business School Supplement 293-068, October 1992. (Revised April 1993.)
Endogenous Productivity of Demand-Induced R&D: Evidence from Pharmaceuticals
When people want more new drugs, firms are happy to invest in ideas that cost more. And as they run out of "low hanging fruit" while demand keeps growing, R&D costs will naturally grow.
Abstract: We examine trends in the productivity of the... View Details
Abstract: We examine trends in the productivity of the... View Details
- 14 Mar 2014
- HBS Seminar
Jeremy M. Levin, former President and CEO, Teva Pharmaceutical Industries
- April 2015
- Supplement
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details
Keywords: LEAD; Leadership And Change Management; Talent Management; Organizational Change and Adaptation; Leadership; Change Management; Talent and Talent Management; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)." Harvard Business School Supplement 415-049, April 2015.
- August 1983
- Case
CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning
Buzzell, Robert D. "CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning." Harvard Business School Case 584-018, August 1983.
- February 2014
- Teaching Note
Mylan Lab's Proposed Merger with King Pharmaceuticals
By: Lucy White
Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details
- August 2001
- Case
Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The
Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian... View Details
Keywords: Competition; Developing Countries and Economies; Business and Government Relations; Pharmaceutical Industry; South Africa; India
Kennedy, Robert E. "Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The." Harvard Business School Case 702-010, August 2001.
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (C): An "At Risk" Launch?
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. Endo Pharmaceuticals (C): An "At Risk" Launch? Harvard Business School Supplement 806-066, January 2006. (Revised May 2007.)
- Article
Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry
By: Leemore S. Dafny, Christopher Ody and Matt Schmitt
The analogy between value-based purchasing in pharmaceuticals and the new frontier of alternative payment models for health care providers is relatively straightforward. Insurers are increasingly demanding steep discounts from providers in exchange for inclusion in... View Details
Keywords: Drug Copayment Coupons; Prescription Drug Policy; Health Care and Treatment; Insurance; Cost; Policy; Pharmaceutical Industry
Dafny, Leemore S., Christopher Ody, and Matt Schmitt. "Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry." New England Journal of Medicine 375, no. 21 (November 24, 2016): 2013–2015.
- August 2012 (Revised January 2013)
- Module Note
Note on Pharmaceutical Reimbursement in the U.S.
By: Regina Herzlinger and Drew Cronin-Fine